Relief Therapeutics Holding SA
Company Profile
Business description
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
Contact
Avenue de Secheron 15
Geneva1202
CHET: +41 225451116
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,143.92 | 92.85 | 1.15% |
DAX 40 | 22,794.11 | 383.84 | 1.71% |
Dow JONES (US) | 43,422.20 | 39.01 | -0.09% |
FTSE 100 | 8,706.59 | 37.92 | 0.44% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,013.33 | 13.06 | -0.07% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,946.62 | 8.63 | -0.14% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |